RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Orphan Drug (Australia), Conditional marketing approval (European Union)

Structure/Sequence

Sequence Code 453739243

Source: *****

Clinical Trials associated with Imlifidase

CTIS2024-517176-38-00

/ Active, not recruitingPhase 2

lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder (DEFEAT NMOSD)

Start Date31 Aug 2025

Sponsor / Collaborator

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

NCT06518005

/ RecruitingPhase 2IIT

An Open-label, Phase 2 Trial to Evaluate the Efficacy and Safety of a Single Intravenous Administration of GNT0003 (an Adeno-associated Viral (AAV) Vector Expressing the UGT1A1 Transgene) Following Imlifidase Pre-treatment in Adult Participants With Severe Crigler-Najjar Syndrome (CNS) Requiring Daily Phototherapy and Presenting Pre-existing Anti-AAV8 Antibodies

Clinical trial rationale:
CNS is an ultra-rare (<1/1 million newborns), autosomal recessive disorder of bilirubin conjugation caused by mutation in the gene coding for uridine 5'-diphosphate glucuronosyltransferase (UGT1A1), that causes the accumulation of neurotoxic unconjugated bilirubin (UCB).
Reduction of UCB is managed with phenobarbital in mild CNS, and daily phototherapy in severe CNS.
There is no authorized curative medical treatment for CNS. Liver transplantation is currently the only curative treatment for severe CNS.
GNT0003 is a genetically modified recombinant (r) viral vector composed of the AAV8 viral capsid carrying the UGT1A1 transgene which aims to correct the dysfunction of the mutated gene by achieving durable expression of a functional copy of the affected gene.
Imlifidase (IgG-degrading enzyme) has demonstrated its efficacy in highly sensitized adult kidney transplant patients.
To give participants with pre-existing anti-AAV8 antibodies access to gene therapy treatments, this trial aims to demonstrate the safety and efficacy of GNT0003 following imlifidase pre-treatment in adult participants with severe CNS requiring daily phototherapy and presenting with pre-existing anti-AAV8 antibodies.
Primary objective: to assess efficacy of a single intravenous administration of GNT0003 following imlifidase pre-treatment in participants with severe CNS requiring phototherapy and pre-existing AAV8 antibodies
Secondary objective: to collect data on safety and tolerability of GNT0003 and imlifidase, efficacy of imlifidase, pharmacokinetic and pharmacodynamic profile of GNT0003, and Quality of Life.
The trial will include 3 parts:
* A baseline period for at least 3 months
* A treatment period
* A follow-up period:
* Initial post-treatment follow-up over 48 weeks
* Long-term follow-up for 4 additional years
This trial will be conducted in accordance with the International Conference on Harmonization Guideline for Good Clinical Practice and the Declaration of Helsinki. Participants must be consented using the approved Informed Consent Form before any procedures specified in the protocol are performed.

Start Date08 Nov 2024

Sponsor / Collaborator

Genethon

[+1]

NCT06461546

/ WithdrawnPhase 2IIT

Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients (LIVEDES)

This is a Phase II, pilot, prospective, unicentric trial, to evaluate Imlifidase could improve the transplantability of the highly sensitized patients with good outcomes respect to survival and functionality of the graft.

Start Date22 Oct 2024

Sponsor / Collaborator-

100 Clinical Results associated with Imlifidase

100 Translational Medicine associated with Imlifidase

100 Patents (Medical) associated with Imlifidase

128

Literatures (Medical) associated with Imlifidase

01 Aug 2026·Transplantation and Cellular Therapy

Imlifidase and EndoS Enables Haploidentical Bone Marrow Engraftment in Sensitized Mice Under Reduced Intensity Conditioning

Article

Author: Petersen, Marcos I ; Anderson, Colin C ; Zhan, Kevin ; Anwar, Perveen ; Bockermann, Robert ; Lin, Jiaxin

Patients in need of a hematopoietic stem cell transplant frequently have pre-existing donor-specific antibodies (DSA) which can impair engraftment. These patients often require more complex conditioning regimens, even in the setting of partially matched (haploidentical) donors. Reducing the complexity and toxicity of conditioning and desensitization protocols is therefore a major goal. We previously showed that enzymatic desensitization of donor-specific IgG using imlifidase and endoglycosidase (EndoS) from S. pyogenes improved murine bone marrow engraftment in donor sensitized, autoimmune-prone recipient mice. Conditioning included a 6 Gy total body irradiation, cyclophosphamide, bortezomib, and T cell depletion. In non-autoimmune prone haploidentical recipients sensitized to the donor, we demonstrate that desensitization with single dose imlifidase and EndoS permits donor bone marrow engraftment in all recipients and long-term chimerism in the majority, under a 3 Gy irradiation protocol. Long-term chimeras were tolerant to subsequent donor skin grafts. Enzymatic inactivation of DSA facilitates donor hematopoietic stem cell engraftment in allo-sensitized haploidentical recipients in a reduced intensity conditioning protocol.

01 Jul 2026·BIODRUGS

Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?

Review

Author: Jourdil, Jean-François ; Stanke-Labesque, Françoise ; Hotot, Marie ; Arrivé, Capucine

The therapeutic arsenal of immunosuppressive drugs in kidney transplantation has recently expanded with the introduction of biologics, approved or used off-label, that specifically target the immune system. Although therapeutic drug monitoring is well established for calcineurin inhibitors, its utility for biological immunosuppressants remains unclear. The objective of this narrative review was to evaluate whether biologics used to prevent or treat renal allograft rejection could be suitable candidates for therapeutic drug monitoring. This review provides (1) a comprehensive and up-to-date synthesis on the pharmacological targets of biologics used in kidney transplantation, (2) assesses the interindividual variability of the pharmacokinetics and pharmacokinetic/pharmacodynamic relationships of key biologics, including belatacept, tocilizumab, rituximab, basiliximab, alemtuzumab, eculizumab, ravulizumab, daratumumab, and imlifidase and (3) describes the analytical methods available for their quantification. This review underscores that, although none of these biologics currently meet all criteria for routine therapeutic drug monitoring, emerging clinical evidence indicates that individualized dosing could enhance both therapeutic outcomes and cost effectiveness. It also discusses future directions for improving pharmacokinetic/pharmacodynamic knowledge on biological therapies in kidney transplant recipients and places in perspective the potential of therapeutic drug monitoring to improve the benefit-risk ratio and cost effectiveness of these biologics.

05 May 2026·BIOCHEMISTRY

Identification and Characterization of Novel Human IgG-Degrading Enzymes

Article

Author: Jones, David H. ; Appling, Francis D. ; Tran, Eileen ; Spraggon, Glen

The human immune response and factors that modulate it represent challenges and opportunities in many areas of medicine. Examples are the threat of transplant rejection and the reduction of this threat by the administration of a bacterially derived immune evasion enzyme. Streptococcus species secrete proteases of the IdeS/Mac family that efficiently degrade host immunoglobulin G (IgG) to help the bacteria evade the host's immune response. IdeS has recently received interest as a tool for transiently ablating circulating IgG in the context of diverse treatments, including transplantation and gene therapy. Given the wide-ranging utility of IdeS-mediated modulation of the human immune response, we sought to explore sequence-function relationships within the IdeS family in the hopes of identifying IdeS enzymes with therapeutic potential. To this end, we developed and applied a structural bioinformatics workflow and analytical strategy to identify and experimentally characterize novel IdeS homologs with activity against human IgG. Multiple IdeS-like enzymes with a range of human IgG degradation efficiencies were identified and characterized. The efficiencies of these enzymes exhibit a nontrivial dependence on the sequence of the IdeS-IgG binding site, highlighting the complexity of substrate recognition by IdeS. The workflow and data presented here inform basic IdeS enzymology, provide novel starting points for engineering IdeS variants for therapeutic use, and suggest general strategies for efficiently sampling protein sequence space to identify therapeutic enzymes.

News (Medical) associated with Imlifidase

24 Aug 2026

·www.fiercepharma.com

Hansa lays groundwork for Nasdaq debut ahead of US kidney transplant drug verdict

With the FDA expected to weigh in on its kidney transplant drug, imlifidase, shortly before year-end, Hansa Biopharma is mulling over its stock listing options in the U.S. Late last week, the Swedish drugmaker said it had submitted draft forms to the Securities and Exchange Commission (SEC) for a possible initial public offering of American Depositary Shares (ADS) in the U.S., plus a proposed private placement in Europe for certain investors. In its securities filing, Hansa clarified that it has yet to decide how many shares to offer, at what price or when. Should the plan progress, Hansa said it aims to trade on the Nasdaq under the HNSA ticker. At the same time, the company says it would maintain the listing of its ordinary shares on Nasdaq Stockholm, where it trades under the same symbol. The paperwork represents a first step by Hansa for a potential U.S. listing. The plan remains subject to Nasdaq and SEC review, the biopharma said with a caveat. Hansa has operated as a commercial-stage drugmaker since 2020, when the European Union cleared the way for imlifidase for desensitization in kidney transplant patients who have difficulty finding an organ match because their bodies produce high levels of antibodies that are meant to attack foreign tissues. The drug has secured green lights in Australia, Norway, Liechtenstein, Iceland, the United Kingdom and Switzerland, as well, where it is marketed under the brand name Idefirix. Now, the company’s commercial fate in the U.S. comes down to an FDA target decision date on imlifidase set for Dec. 19. Hansa reported positive U.S. phase 3 results on the antibody-cleaving enzyme for desensitization treatment in highly sensitive kidney patients late last September, paving the way for its FDA filing. Patients in the study who received Hansa’s drug charted statistically significant improvements in kidney function, as tracked by estimated glomerular filtration rate (eGFR), at the one-year mark, helping the trial meet its primary endpoint. At the time, Hansa’s chief operating officer and U.S. chief, Maria Törnsén, noted on a call that “[t]he unmet needs in the U.S. kidney transplant market are significant.” The highly sensitized patients Hansa is targeting make up about 10% to 15% of the roughly 100,000 people on the U.S. kidney transplant list, she added. In another potential signal toward Hansa’s intended focus on the U.S. market, the company in May agreed to sell Idefirix development and commercialization rights in the EU, U.K., Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa region to privately held SERB Pharmaceuticals, pocketing 115 million euros in the process. The deal closed on July 1, with Hansa’s CEO, Renée Aguiar-Lucander, noting in an announcement that the transaction “strengthens Hansa’s financial position as we continue to prepare for a potential US launch of imlifidase, subject to US approval, and advance our broader R&D pipeline.”

Clinical ResultPhase 3

21 Aug 2026

·allsci.com

Hansa aims for secondary US listing ahead of FDA decision on kidney transplant therapy

Sweden-based Hansa Biopharma AB (Nasdaq Stockholm: HNSA), a commercial-stage immunology company with an EU-approved enzyme therapy and a pending US FDA decision due in December, has submitted a confidential draft Form F-1 registration statement to the SEC for a potential US offering and listing of American Depositary Shares (ADSs) on the Nasdaq Global Market under the ticker HNSA. The company is also considering a concurrent private placement of ordinary shares to qualified investors in Europe. The proposed transaction would effectively give Hansa a secondary US listing while retaining its existing Nasdaq Stockholm listing. The ADS-to-share ratio, offering size, price range, and use of proceeds have not yet been determined, and completion remains subject to market and other conditions. In March 2026, Hansa secured USD 30 million in convertible senior notes from funds managed by Athyrium Capital Management, extending its cash runway into mid-2027. A US listing could broaden the company's access to specialist biotech investors as it approaches a major regulatory catalyst for its lead asset. Hansa's lead product, imlifidase (Idefirix), is a first-in-class IgG-cleaving enzyme conditionally approved in the EU, Australia, and Switzerland for desensitization of highly sensitized kidney transplant patients. The US FDA accepted Hansa's Biologics License Application (BLA) in February 2026 and assigned a December 19, 2026 Prescription Drug User Fee Act (PDUFA) action date. The pivotal Phase III ConfIdeS trial met its primary endpoint with statistical significance (p<0.0001), according to the company. The timing of the proposed US listing therefore comes ahead of a potentially significant expansion of Hansa's commercial footprint. Imlifidase is not currently approved in the US, where highly sensitized kidney transplant candidates are managed using approaches including plasmapheresis and intravenous immunoglobulin rather than an approved IgG-cleaving desensitization therapy. Hansa's pipeline also includes HNSA-5487, a next-generation IgG-cleaving enzyme being developed for Guillain-Barré syndrome. Access the AllSci platform to explore the science behind the news. Spot something wrong? Report an issue with this article

Phase 3Drug ApprovalClinical ResultGene Therapy

18 Aug 2026

·www.prnewswire.com

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). "This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with the Australian transplant community to build experience with Idefirix across both living and deceased donor transplantations." Patient outcomes will be documented through an established registry in Australia. Data from real-world clinical use will be collected and may contribute to future scientific publications, and help to further the understanding of the use of Idefirix in living donor transplants. Idefirix is approved in Australia as a desensitization treatment of highly sensitized adult kidney transplant candidates who have a positive cross-match against a living or deceased donor. Contacts for more information: Kerstin Falck, VP Global Corporate Affairs [email protected] [email protected] Notes to editors About highly sensitized patients Highly sensitized patients have pre-formed antibodies called donor specific antibodies (DSAs) with a broad reactivity against human leukocyte antigens (HLAs), which can cause tissue damage and potentially transplant rejection.1 The presence of DSAs means that highly sensitized patients tend to have limited or no access to transplant, as finding a compatible donor organ can be particularly challenging.2,3 The complexity of their immunological profile means that highly sensitized patients spend longer time than average on transplant waiting lists, with evidence showing that this longer time waiting for a suitable donor relates to an increased mortality risk.4,5 Across the U.S. and Europe, highly sensitized patients comprise around 10-15% of the total of patients on transplant waiting lists.6,7 About imlifidase Imlifidase is conditionally approved in the European Union, Norway, Liechtenstein, Iceland and the UK under the tradename Idefirix® for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive cross-match against an available deceased donor. Idefirix® is also approved in Australia, Israel and Switzerland. Information about the trial is available at ClinicalTrials.gov: NCT04935177 About IDEFIRIX ® (imlifidase) Imlifidase is an antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets and cleaves immunoglobulin G (IgG) antibodies and inhibits IgG-mediated immune response.8 It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. Imlifidase has conditional marketing approval in Europe and is marketed under the trade name Idefirix for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive cross-match against an available deceased donor. The use of Idefirix should be reserved for patients who are unlikely to be transplanted under the available kidney allocation system, including prioritization programs for highly sensitized patients.8 Idefirix was reviewed as part of the European Medicines Agency's (EMA) PRIority Medicines (PRIME) program, which supports medicines that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options.8 The efficacy and safety of imlifidase as a pre-transplant treatment to reduce donor-specific IgG antibodies was studied in four phase 2 single-arm, studies in EU and US as well as a randomized, controlled Phase 3 study in US.5,7,10-11 Hansa is collecting further clinical evidence and will submit additional efficacy and safety data based on one observational follow-up study and one post-approval efficacy study. In the US, the Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for imlifidase in February of 2026 and assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. Full EU product information can be accessed via the initial Summary of Product Characteristics found here. About kidney failure Kidney disease can progress to kidney failure or End-Stage Renal Disease (ESRD), identified when a patient's kidney function is less than 15%.12 ESRD poses a significant health burden, affecting nearly 2.5 million patients worldwide.12 A kidney transplant is the treatment of choice for suitable patients with ESRD because it offers improved survival and quality of life benefits, and is cost savings compared to long-term dialysis. There are approximately 170,000 kidney patients in the U.S. and Europe waiting for a new kidney.13 About Hansa Biopharma Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at and follow us on LinkedIn. ©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, Idefirix, and Idefirix flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved. Forward-Looking Statements This press release contains forward-looking statements relating to the business of Hansa, including, without limitation, statements regarding Hansa's commercial activities in Australia. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. Hansa cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Hansa disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Hansa's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. References Eurostam Report (A Europe-wide strategy to enhance transplantation of highly sensitized patients on the basis of acceptable HLA mismatches.) Available at . Redfield RR, et al. The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients. Nephrol Dial Transplant. 2016 Oct;31(10):1746-53. doi: 10.1093/ndt/gfw099. Lonze BE, et al. IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-strength Donor-specific Antibody. Ann Surg. 2018 Sep;268(3):488-496. doi: 10.1097/ Alelign T, Ahmed MM, Bobosha K, Tadesse Y, Howe R, Petros B. Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. J Immunol Res. 2018 Mar 5;2018:5986740. Available at: Heidt S, et al. Highly Sensitized Patients are Well Serves by Recieving a Compatible Organ Offer Based on Acceptable Mismatches. Front Immunol. 2021;12:687254. Available at: Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2022 Annual Data Report. U.S. Department of Health and Human Services, Health Resources and Services Administration; 2024. Accessed [June 2024]. Jordan SC, et al. Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes). Transplantation. 2021 Aug 1;105(8):1808-1817. doi: 10.1097/TP.0000000000003496. European Medicines Agency. Idefirix® summary of product characteristics. Available at: . Jordan SC, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med 2017;377:442-453. DOI: 10.1056/NEJMoa16125 1Winstedt L, et al. Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic Opportunity. PLoS One. 2015 Jul 15;10(7):e0132011. doi: 10.1371/journal.pone.0132011. PMID: 26177518; PMCID: PMC4503742. Lorant T, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018 Nov;18(11):2752-2762. doi: 10.1111/ajt.14733. NIH (2018). What is kidney failure? Available at: . Newsletter Transplant 2022. International figures on donation and transplantation. Available at: Newsletter Transplant - latest edition I Freepub (edgm.eu) Accessed: May 2024 This information was brought to you by Cision The following files are available for download: SOURCE Hansa Biopharma AB 21% more press release views with Request a Demo

Drug ApprovalPhase 3Clinical ResultPhase 1Immunotherapy

100 Deals associated with Imlifidase

External Link

KEGG	Wiki	ATC	Drug Bank
D11470	Imlifidase	L04AA41	DB15258

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Renal transplant rejection	European Union	Hansa Biopharma AB	25 Aug 2020
Renal transplant rejection	Iceland	Hansa Biopharma AB	25 Aug 2020
Renal transplant rejection	Liechtenstein	Hansa Biopharma AB	25 Aug 2020
Renal transplant rejection	Norway	Hansa Biopharma AB	25 Aug 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anti-Glomerular Basement Membrane Disease	Phase 3	United States	Hansa Biopharma AB	22 Dec 2022
Anti-Glomerular Basement Membrane Disease	Phase 3	Austria	Hansa Biopharma AB	22 Dec 2022
Anti-Glomerular Basement Membrane Disease	Phase 3	Belgium	Hansa Biopharma AB	22 Dec 2022
Anti-Glomerular Basement Membrane Disease	Phase 3	Czechia	Hansa Biopharma AB	22 Dec 2022
Anti-Glomerular Basement Membrane Disease	Phase 3	Denmark	Hansa Biopharma AB	22 Dec 2022
Anti-Glomerular Basement Membrane Disease	Phase 3	France	Hansa Biopharma AB	22 Dec 2022
Anti-Glomerular Basement Membrane Disease	Phase 3	Germany	Hansa Biopharma AB	22 Dec 2022
Anti-Glomerular Basement Membrane Disease	Phase 3	Ireland	Hansa Biopharma AB	22 Dec 2022
Anti-Glomerular Basement Membrane Disease	Phase 3	Italy	Hansa Biopharma AB	22 Dec 2022
Anti-Glomerular Basement Membrane Disease	Phase 3	Netherlands	Hansa Biopharma AB	22 Dec 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03611621 (17-HMedIdeS-14, PRNewswire)	Phase 1/2	Renal transplant rejection --	39	Imlifidase	tbocpshzxk(rbibgjydcy) = hxotrtanze orbbokxvki (qjopcelues ) View more	Positive	30 Jun 2025
NCT03943589 (15-HMedIdeS-09, CTgov)	Phase 2	Guillain-Barre Syndrome	30	Imlifidase	zceqngwffa(zokokyfwxl) = pzhderozvt ocqkkerrak (ningmxresw, hypfjfzayz - itlcybsmre) View more	-	09 Apr 2025
NCT05049850 (CTgov)	Phase 2	Renal transplant rejection	3	Imlifidase	oalrfbzcer = tlkwxlbduq rqhdsalesc (rhahkreqqr, ncydrtnqur - areeiilepe) View more	-	17 Mar 2025
NCT03943589 (15-HMedIdeS-09, PRNewswire) Manual	Phase 2	Guillain-Barre Syndrome	30	imlifidase	ugfkzkbsug(xbungswgxb) = pbxbvjugai fujrhhvtvk (ijralzppiw ) View more	Positive	17 Dec 2024
NCT04711850 (EudraCT number: 2018-000022-66, 2020-004777-49, Pubmed \| Clin Transplant)	Not Applicable	Renal transplant rejection DSA	-	Imlifidase	oatgqtaqta(ynjpdqaapo) = xlhhdhncxu gxbnzhwdfo (bmbmvivawi ) View more	Negative	01 Jul 2024
				Imlifidase (Plasmapheresis)	oatgqtaqta(ynjpdqaapo) = hlqdyyfhfh gxbnzhwdfo (bmbmvivawi ) View more
NCT03897205 (16-HMedIdes-12, CTgov)	Phase 2	Antibody-mediated rejection \| Renal transplant rejection	30	Imlifidase (Imlifidase)	sddhmsaqsm(nvxdkmjgtp) = qpqqqrsdsd vwmuwujpzl (qgfcyfsrud, 4) View more	-	28 Feb 2024
				Plasma Exchange (Plasma Exchange)	sddhmsaqsm(nvxdkmjgtp) = ovcbzjykqa vwmuwujpzl (qgfcyfsrud, 26) View more
NCT03157037 (GOOD-IDES-01, Pubmed \| Nephrol Dial Transplant)	Phase 2	Anti-Glomerular Basement Membrane Disease anti-GBM antibodies \| EA and EB epitopes \| IgG subclass ... View more	15	Imlifidase	musblkstks(iuzyrwqgvf) = grfgmlipgt hsnhvidlly (nwfimrkccm ) View more	Positive	20 Dec 2023
				imlifidase (Plasmapheresis)	xkmbozsdel(qgirmoelya) = lhdarioecx pohlodemwm (mwufvryign )
NCT03897205 (16-HMedIdes-12, PRNewswire) Manual	Phase 2	AMR Syndrome	30	imlifidase	gpleztjbuu(ivaseigibh) = mimmuqmmnn tzrnemrogr (ijdhcuxaaq ) View more	Positive	14 Dec 2023
				standard of care	gpleztjbuu(ivaseigibh) = hogsadcjiu tzrnemrogr (ijdhcuxaaq ) View more
NCT03943589 (15-HMedIdeS-09, Biospace) Manual	Phase 2	Guillain-Barre Syndrome	-	imlifidase+ intravenous immunoglobulin	ebjaxysbub(tuapeeezjj) = Imlifidase was safe and well tolerated rtadkgecgb (ktrwwlgypm ) View more	Positive	07 Dec 2023
NCT03897205 (Biospace) Manual	Phase 2	Graft Rejection	30	Imlifidase	zjtehkqhhk(jrmkewpywo) = With regard to safety, imlifidase was well tolerated, and no safety signals were encountered during the study qihkiomziy (ergxtobfrw )	Positive	28 Nov 2022
				plasma exchange

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis